GLP-2 (TZ)

CAS 2023788-19-2 · Metabolic Research

10 MG

$50.00

✔ ORDER NOW · SHIPS TODAY

Bulk Discount

⚠ RESEARCH USE ONLY

This product is sold strictly for in vitro laboratory research use only. Not for human or animal consumption, diagnostic use, or therapeutic application. Purchasers must be qualified researchers or authorized purchasers for a research institution.

CERTIFICATE OF ANALYSIS

Third party tested for: Purity · ID · Quantity

BATCH #2607030615
View All →

View on PubChem→

Tirzepatide Overview

Tirzepatide is a synthetic 39-amino-acid peptide engineered as a dual agonist targeting both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Its balanced activity at both incretin receptors distinguishes it from earlier GLP-1 mono-agonists and positions it as a widely-studied research tool in metabolic biology.

In research models, tirzepatide has been examined for glucose-dependent insulin secretion, appetite signaling, gastric-emptying kinetics, and combined incretin-pathway effects on body composition and glycemic control.

Reference: Coskun T. et al. (2018), Molecular Metabolism, 18, 3-14.

History

Tirzepatide emerged from research programs at Eli Lilly investigating dual-incretin receptor activation as a strategy beyond single-receptor GLP-1 agonism. Preclinical work characterized the molecule as a GIPR-biased dual agonist with a fatty-acid-modified backbone enabling once-weekly dosing profiles. It was first described in the peer-reviewed literature in 2018 and subsequently studied across a range of preclinical metabolic models.

Reference: Frias J. P. et al. (2018), The Lancet, 392(10160), 2180-2193.

Tirzepatide Structure

CAS #: 2023788-19-2

Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈

Molecular Weight: 4,813.53 g/mol

PubChem CID: 156588324

Research Findings

Tirzepatide has been examined across preclinical rodent, non-human primate, and human research settings. Reported findings describe dual activation of GIPR and GLP-1R with GIPR-biased signaling, glucose-dependent insulin secretion, delayed gastric emptying, appetite regulation via central pathways, and dose-dependent effects on body weight and glycemic parameters.

Key Areas of Research:

Incretin signaling: Dual GIPR and GLP-1R receptor pharmacology
Glucose regulation: Glucose-dependent insulin secretion
Appetite pathways: Central-nervous-system feeding circuits and satiety
Body composition: Fat-mass reduction and lean-mass preservation

Together, these observations position tirzepatide as a widely-used research tool for studying dual-incretin receptor activation across metabolic and body-composition biology.

References: Jastreboff A. M. et al. (2022), NEJM, 387(3), 205-216; Rosenstock J. et al. (2021), The Lancet, 398(10295), 143-155.

References

Coskun T. et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist. Molecular Metabolism, 18, 3-14.
Frias J. P. et al. (2018). Efficacy and safety of LY3298176 versus dulaglutide in patients with type 2 diabetes. The Lancet, 392(10160), 2180-2193.
Jastreboff A. M. et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216.
Rosenstock J. et al. (2021). Efficacy and safety of tirzepatide monotherapy compared with dulaglutide. The Lancet, 398(10295), 143-155.
Willard F. S. et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 5(17), e140532.

Frequently Asked Questions

Everything you need to know about our products and processes.

10 mg of lyophilized tirzepatide powder, matching the amount printed on the label. Research-grade purity supports careful protocol design.

Every order comes with a complimentary vial of bacteriostatic water for reconstitution. Any additional lab supplies (syringes, filter needles, mixing vessels) need to be sourced by your institution.

Sealed lyophilized peptide typically holds stability for around 2 years under proper cold, dry, dark storage. Once reconstituted, refrigerate and use within a few weeks depending on your lab’s handling conditions.

No. Product ships strictly for in vitro laboratory research. Since tirzepatide in this form isn’t authorized for human or animal use outside approved research settings, we don’t provide protocols or dosing guidance.

Every batch we ship is validated at 98% purity or higher via HPLC and mass spectrometry, and a Certificate of Analysis is available for the specific batch you receive.

Lyophilized form: keep cool, dry, and away from direct light. Reconstituted: refrigerate and try to avoid repeated temperature swings that could affect peptide integrity.